Trial Profile
Efficacy and safety of three doses of vildagliptin in drug naive patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 04 May 2012 Actual end date Jul 2006 added as reported by ClinicalTrials.gov.
- 19 Jan 2007 Status changed from in progress
- 29 Nov 2005 New trial record.